Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background

Acute coronary syndrome (ACS) is a term representing all diseases related to reduction in blood flow to the heart characterised by clot formation over a segment of blood vessel narrowing. A major constituent of clot are blood cells called platelets and many of the medications used in ACS target platelet function. Ticagrelor is known to reduce platelet activity in clot formation by blocking a specific step in the process (P2Y12 receptors). A recent study has found that the presence of ticagrelor may also reduce clot formation by significantly enhancing another process involving the molecule nitric oxide (NO). This is of particular interest if translates into clinical practice, as many patients with heart disease have abnormal function of their blood vessel lining. This is known to cause a reduction in available nitric oxide. Does this therefore mean these patients will have a reduced response to ticagrelor therapy and subsequently be at increased risk of clot formation?

Aims

1. Will ticagrelor increase the anti clot effect of vessel lining produced nitric oxide?
2. Do patients with diabetes or smokers, who have poor function of their vessel lining, have a reduced response to ticagrelor?

Methods

This is a pilot study in which we propose to look at 64 patients with known disease of their heart blood vessels, with an equal mix of smokers, diabetics, smoking diabetics and non smoking non diabetics. We will also recruit ten healthy normal subjects to ensure that our tests produce the same results as the basic science study mentioned above.

To answer the questions posed we will perform blood tests, primarily looking at platelet function, and non-invasive blood vessel lining assessment. This will be done before and after ticagrelor treatment on each participant, enabling statistical comparison.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI

NCT02012140

Cardiovascular Disease Stable Angina Myocardial Infarction +1 more

UNKNOWN PHASE4

Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome

NCT01626534

Acute Coronary Syndrome

COMPLETED PHASE3

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

NCT02052635

Non-ST Elevation Acute Coronary Syndrome

TERMINATED PHASE4

Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

NCT02071966

Non ST Segment Elevation Acute Coronary Syndrome

TERMINATED PHASE4

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

NCT02925923

Acute Coronary Syndrome Angina, Unstable

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Coronary Artery Disease

Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)

Group Type OTHER

Ticagrelor

Intervention Type DRUG

Blood tests taken for flow cytometry

EndoPAT - endothelial assessment

Intervention Type OTHER

Healthy Normals

Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)

Group Type OTHER

Ticagrelor

Intervention Type DRUG

Blood tests taken for flow cytometry

EndoPAT - endothelial assessment

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ticagrelor

Blood tests taken for flow cytometry

Intervention Type DRUG

EndoPAT - endothelial assessment

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

blood test

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* Coronary artery disease deemed to require Percutaneous Coronary Intervention
* Diabetics must be established on oral or subcutaneous therapy
* Non diabetics must have HbA1c levels between 20-42 mmol/mol
* Current smokers are those that have smoked greater than 100 cigarettes and currently smoke on a daily basis
* Non smokers have not smoked for greater than 3 years (and not on nicotine replacement)
* Healthy controls are non smokers without medical history and taking no regular medication

Exclusion Criteria

* Contra-indication to dual antiplatelet therapy

* Known bleeding disorders
* Known malignant disease
* Known myeloproliferative disease/malignant paraproteinaemia/heparin induced thrombocytopenia
* Previous intracranial bleed
* Already established on dual antiplatelet therapy
* Known moderate-severe liver or splenic failure
* Severe renal impairment
* Major surgery due within one month of enrolment or before completion of measurements
* Known allergy/intolerance to aspirin or ticagrelor
* Reaction or side effect of aspirin or ticagrelor resulting in discontinuation prior to completion
* Known allergy/intolerance to 3-hydroxy-3-methylglutaric acid Coenzyme A reductase inhibitor therapy (statins)
* Concurrent use of high dose simvastatin/lovastatin (\>40mg daily)
* Currently taking medication that will interact with platelet function ie NSAIDS, antibiotics or herbal remedies
* Concurrent use of strong cytochrome P450 3A4 inhibitors eg. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir
* Concurrent use of strong cytochrome P450 3A4 inducers e.g. rifampicin, dexamethasone, phenytoin, carbamazepine and phenobarbital
* Known sick sinus syndrome, second or third degree AV block or bradycardia-related syncope without permanent pacemaker in situ
* Known severe asthma/Chronic Obstructive Pulmonary Disease or worsening of dyspnoeic symptoms on ticagrelor
* Known severe gout
* Currently taking calcium channel antagonist
* Currently taking long acting nitrate
* Currently taking \>15mg/week of methotrexate
* Women pregnant, breast feeding or of child bearing potential
* Require anticoagulation on warfarin or Novel Oral AntiCoagulant
* Platelet count \<150 x109/L or \>400 x109/L
* Known blood bourne virus carrier
* Unable to give informed consent
* Involvement in a conflicting study
* Non English speaker

* Develop significant bleeding complications of medication requiring discontinuation of antiplatelet therapy prior to completion of the study
* Urgent surgery undertaken during the study resulting in discontinuation of antiplatelet therapy prior to completion of the study
* React or develop side effects of aspirin or ticagrelor resulting in discontinuation prior to completion of the study
* Commence medication that will interact with platelet function before completion of the study
* Commence use of strong cytochrome P450 3A4 inhibitors before completion of the study
* Commence use of strong cytochrome P450 3A4 inducers before completion of the study
* Worsening of dyspnoea in subjects with mild/moderate asthma/Chronic Obstructive Pulmonary Disease resulting in discontinuation of ticagrelor prior to completion of the study
* Platelet count on initial sampling \<150 x109/L or \>400 x109/L
* Non diabetic patients HbA1c level \>42 mmol/mol
* Noncompliance with medication
* Subject wishes to no longer participate in the study (no reason or time period required)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes